Avalo Therapeutics (AVTX) Competitors $11.25 -0.45 (-3.85%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$11.18 -0.06 (-0.58%) As of 09/23/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. PRME, IVA, OLMA, AQST, CMPS, CMPX, BCYC, KOD, ETON, and ARCTShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Prime Medicine (PRME), Inventiva (IVA), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Prime Medicine Inventiva Olema Pharmaceuticals Aquestive Therapeutics COMPASS Pathways Compass Therapeutics Bicycle Therapeutics Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics Avalo Therapeutics (NASDAQ:AVTX) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Do analysts recommend AVTX or PRME? Avalo Therapeutics presently has a consensus price target of $31.67, indicating a potential upside of 181.48%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Avalo Therapeutics is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, AVTX or PRME? Avalo Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Do insiders & institutionals have more ownership in AVTX or PRME? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by insiders. Comparatively, 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is AVTX or PRME more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Avalo Therapeutics' return on equity of -48.48% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Prime Medicine -4,016.83%-156.16%-64.41% Does the media prefer AVTX or PRME? In the previous week, Avalo Therapeutics had 2 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Avalo Therapeutics and 6 mentions for Prime Medicine. Avalo Therapeutics' average media sentiment score of 0.72 beat Prime Medicine's score of 0.17 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, AVTX or PRME? Avalo Therapeutics has higher earnings, but lower revenue than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K336.22-$35.13MN/AN/APrime Medicine$4.96M146.21-$195.88M-$1.56-3.46 SummaryAvalo Therapeutics beats Prime Medicine on 11 of the 14 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.88M$2.55B$5.76B$10.51BDividend YieldN/A53.63%5.53%4.57%P/E RatioN/A23.4076.0626.61Price / Sales336.22513.39472.8291.51Price / CashN/A171.0137.4661.85Price / Book0.885.3813.586.45Net Income-$35.13M$32.95M$3.29B$271.57M7 Day Performance-0.71%3.00%1.83%2.61%1 Month Performance13.87%4.89%4.02%7.28%1 Year Performance15.38%0.71%77.05%29.60% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.9509 of 5 stars$11.25-3.8%$31.67+181.5%+16.3%$153.88M$440K0.0040PRMEPrime Medicine0.5001 of 5 stars$4.01-1.5%N/AN/A$547.72M$2.98M0.00N/AIVAInventiva3.1006 of 5 stars$5.31-5.3%$14.83+179.3%+158.9%$536.67M$9.95M0.00100Upcoming EarningsGap UpOLMAOlema Pharmaceuticals2.5596 of 5 stars$8.00+3.0%$24.00+200.0%-32.3%$533.29MN/A-4.0470AQSTAquestive Therapeutics1.8364 of 5 stars$5.14+1.8%$10.29+100.1%+6.6%$503.61M$44.13M-7.34160CMPSCOMPASS Pathways2.9471 of 5 stars$5.14-1.2%$16.29+216.8%-27.8%$498.89MN/A-2.79120Positive NewsCMPXCompass Therapeutics1.9056 of 5 stars$3.69+3.4%$13.88+276.0%+112.6%$493.67M$850K-8.2020BCYCBicycle Therapeutics3.1083 of 5 stars$6.86-3.0%$22.22+223.9%-70.4%$490M$19.28M-1.95240KODKodiak Sciences2.5833 of 5 stars$9.35+1.1%$11.75+25.7%+446.6%$488.60MN/A-2.4690Analyst ForecastETONEton Pharmaceuticals1.8714 of 5 stars$17.78+0.7%$29.67+66.9%+240.1%$473.34M$58.18M-111.1320Positive NewsARCTArcturus Therapeutics2.7616 of 5 stars$18.13+4.7%$50.57+178.9%-4.2%$470.32M$152.31M-8.13180Positive News Related Companies and Tools Related Companies Prime Medicine Competitors Inventiva Competitors Olema Pharmaceuticals Competitors Aquestive Therapeutics Competitors COMPASS Pathways Competitors Compass Therapeutics Competitors Bicycle Therapeutics Competitors Kodiak Sciences Competitors Eton Pharmaceuticals Competitors Arcturus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTX Stock Alerts